Skip to main content

CombiMatrix Value Stock - Dividend - Research Selection


ISIN: US20009T5011 , WKN: A2AD52

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary CombiMatrix Molecular Diagnostics, Inc., based in Irvine, California. The company operates as a diagnostic reference laboratory that offers DNA-assisted clinical diagnostic testing to physicians, hospitals, clinics and other laboratories in the field of pre- and post-natal developmental disorders as well as hematology / oncology genomics. The company's BAC arrays enable the company to conduct aCGH studies to assess genomic changes. The company's oligo arrays enable the company to execute aCGH on a much finer scale than BAC technology can. For the year ended December 31, 2011, the Company also owns a 33% interest in Leuchemix, Inc. (Leuchemix), a privately-held drug development company focused on the development of a range of compounds for the treatment of a range of oncologically-related diseases.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,